Quizartinib is a kinase inhibitor indicated for adult patients with newly diagnosed acute myeloid leukemia (AML) who have been confirmed to carry the FLT3 internal tandem duplication (FLT3-ITD) mutation by an FDA-approved detection method. This drug is used in combination with standard chemotherapy during the induction and consolidation phases, and as a single-agent maintenance therapy after consolidation chemotherapy.

What Are the Purchase Channels for Quizartinib?

Overseas Purchase

Patients may choose to consult and purchase Quizartinib at hospital pharmacies or legitimate drugstores in countries or regions where the drug has been marketed.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan well before purchasing.

Purchase through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for the Use of Quizartinib

Pre-Medication Assessment Requirements

ECG Monitoring: QTcF monitoring is required at baseline, once a week during the induction and consolidation phases, and once a week in the first month of the maintenance phase.

Electrolyte Testing: Hypokalemia and hypomagnesemia must be corrected.

Contraindication Screening: Quizartinib is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, and long QT syndrome.

Dosage Management Standards

Induction Phase: 35.4 mg once daily (from Day 8 to Day 21).

Consolidation Phase: 35.4 mg once daily (from Day 6 to Day 19).

Maintenance Phase: 26.5 mg once daily from Day 1 to Day 14 of the first cycle; if QTcF ≤ 450 ms after Day 15, the dosage can be increased to 53 mg once daily.

Management of Missed Doses: If a dose is missed, take it as soon as remembered on the same day; resume the normal dosing schedule on the next day. Doubling the dose on the same day is prohibited.

Drug Interaction Warnings

Strong CYP3A Inhibitors (e.g., ketoconazole): The dosage of Quizartinib needs to be reduced.

Strong/Moderate CYP3A Inducers (e.g., rifampicin): Concomitant use is prohibited.

Drugs That Prolong the QT Interval (e.g., fluoroquinolones): Enhanced ECG monitoring is required.

Management of Special Populations

Pregnant Women: Quizartinib has embryo-fetal toxicity, so effective contraception must be used during the medication period.

Lactating Women: Breastfeeding is prohibited during treatment and within 1 month after the last dose.

Authenticity Identification of Quizartinib

Verification of Appearance Characteristics

17.7 mg Tablets: White, round, film-coated tablets engraved with "DSC511".

26.5 mg Tablets: Yellow, round, film-coated tablets engraved with "DSC512".

Confirmation of Packaging Information

Authentic products use child-resistant packaging.

The label must fully include the drug name, specification, batch number, and expiration date.